Remepy Overview
Remepy is pioneering hybrid drugs, and redefining combination therapy. Its mission is to bring better personalized care to patients. Remepy’s Digital molecules are mobile applications designed for hybrid drug experiences, each containing a unique digital treatment protocol. Its Digital molecules include digitized, standardized, evidence-based interventions, designed to enhance brain plasticity and connectivity, balance the immune system, and drive behavioral changes. The company addresses disease end-points as well as side-effects and disease comorbidities. Remepy partners with pharma companies to bring Hybrid Drugs to market that will combine Remepy’s Digital Molecule and traditional drug components.
Cumulative Funding Raised Over Time ($)
$5.0MDec 2022
$15.0MMar 2025
$25.0MMay 2024
Latest News
growth-positive
Remepy To Embed AI In Next-Gen Digital Therapeutics For Personalized Neuroimmune Modulation
Remepy is advancing its RMPY-008 app by incorporating adaptive sequencing, journaling tools, and phenotyping capabilities. The company is exploring two regulatory pathways to integrate software and drug into a single therapeutic entity. The first pathway involves a combination product approach, while the second utilizes the FDA’s Prescription Drug Use-Related Software (PDURS) pathway. The RMPY-008 app delivers its protocol through cognitive-emotional tasks and sensory modulation, aiming to enhance therapeutic outcomes.
growth-positive
Remepy's Mobile App Shown to Rewire Brain, Modulate Immune System and Improve Mood in Adults with Subjective Cognitive Decline
Remepy, a pioneer in hybrid drugs integrating digital and pharmacological interventions, announced that its app-based intervention, RMPY-008, demonstrated significant modulation of inflammatory blood biomarkers in a clinical trial. The study, involving 103 adults, showed that the digital intervention reduced depressive symptoms and improved brain connectivity in individuals with subjective cognitive decline. The findings suggest that RMPY-008 can modulate both brain and immune functions, offering a new therapeutic modality. The app achieved high adherence and engagement, with participants showing sustained benefits. Remepy is commercializing its platform in collaboration with pharmaceutical partners, focusing initially on Parkinsons disease, with plans to expand into fertility, oncology, and immunology.
Product StagePartners
growth-positive
Remepy co-founder Michal Tsur told the Israel Business Conference about the therapy revolution whose time has come.
Remepy, a company co-founded by Dr. Michal Tsur, is pioneering the development of hybrid medications, combining digital applications with traditional drugs. At the 2024 Globes Israel Business Conference, Tsur highlighted the potential of these medications, particularly for Parkinsons disease, following a successful clinical trial. The company aims to revolutionize the pharmaceutical industry by integrating digital treatment protocols with chemical elements, enhancing treatment accessibility and effectiveness. Additionally, Tsur is exploring the establishment of a new airline to offer affordable flights, addressing the current scarcity and high cost of air travel to and from Israel. This initiative reflects the broader trend of high-tech entrepreneurship addressing public sector gaps. Tsur emphasizes the importance of private sector innovation in improving public life, advocating for proactive solutions to societal challenges.
growth-positive
Israeli Startup Combines Software With Medicine To Transform Pharma
Remepy, an Israeli startup, is pioneering the development of hybrid drugs by combining software with traditional medicine. The company has successfully closed a $10 million seed investment round, bringing its total funding to $15 million. The investment was led by NFX and included several other venture firms. Remepy aims to standardize and personalize therapeutic interventions using digital molecules, which have shown promising results in early clinical studies. The company plans to target diseases like Parkinson’s, neurodegenerative diseases, and cancer. Remepy has also announced new board members, including Danny Bar Zohar from Merck and former Israeli Prime Minister Naftali Bennett. The companys approach could potentially halve the time required to bring new drugs to market.
InvestmentManagement ChangesProduct Stage
growth-positive
Remepy raises $10 million Seed round to bring first hybrid drug to market | CTech
Israeli startup Remepy has raised $10 million in a seed investment round, bringing its total funding to $15 million. The round was led by NFX and included participation from Vine Ventures, Psymed Ventures, Supernode Ventures, and Firstime Ventures, among others. Remepy is developing hybrid drugs that combine traditional drugs with its digital molecules, therapeutic interventions that trigger physiological effects through the brain. The company has shown promising results in human studies for Oncology, MCI, and Parkinson’s Disease. Dr. Danny Bar Zohar, Merck’s Global head of R&D and Chief Medical Officer, will be joining the board.
InvestmentManagement Changes
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $25M |
| Last funding | $10M |
| Stage | Seed |
| Rounds | 3 |
| Investors | 9 |
Team Members
4
Employees: 51-200
Web & Social Links
| Website | www.remepy.com/ |
| Careers | Careers page |
Locations
Ramat Gan, Israel
Photos & Videos
No files yet
Remepy Business
Business models
B2B, B2B2C
Product stage
Clinical Trial
Employees
51-200
Sector
Health Tech & Life SciencesDigital HealthcareMedical Decision SupportPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
Platforms & InterfacesSoftwareTags (5)
digital-healthcaresaasdrug-discoverydrug-developmentpharmaceuticalsGeographic Markets
United StatesRemepy Financials
$25M
Total funding
Undisclosed
Capital raised
$10M
Last funding
Seed
Funding stage
3
Total rounds
9
Investors
Cumulative Funding Raised Over Time ($)
$5.0MDec 2022
$15.0MMar 2025
$25.0MMay 2024
Private Equity Funding
Seed
Mar 2025
$10M
Seed
May 2024
$10M
NFX Capital (Lead)
,
Vine Ventures, Psymed Ventures, TechAviv Founder Partners, Supernode Ventures, Firstime VC, 97212 Ventures
Seed
Dec 2022
$5M
Fresh Fund (Lead)
,
TechAviv Founder Partners, Samsung Next TLV, Supernode Ventures
Remepy Lifecycle
Cumulative Funding Raised Over Time
$5.0MDec 2022
$15.0MMar 2025
$25.0MMay 2024
All Events
Seed
Mar 2025
$10M
Seed
May 2024
$10M
NFX Capital (Lead)
,
Vine Ventures, Psymed Ventures, TechAviv Founder Partners, Supernode Ventures, Firstime VC, 97212 Ventures
Seed
Dec 2022
$5M
Fresh Fund (Lead)
,
TechAviv Founder Partners, Samsung Next TLV, Supernode Ventures
Remepy News
7 articles
growth-positive
Remepy To Embed AI In Next-Gen Digital Therapeutics For Personalized Neuroimmune Modulation
Remepy is advancing its RMPY-008 app by incorporating adaptive sequencing, journaling tools, and phenotyping capabilities. The company is exploring two regulatory pathways to integrate software and drug into a single therapeutic entity. The first pathway involves a combination product approach, while the second utilizes the FDA’s Prescription Drug Use-Related Software (PDURS) pathway. The RMPY-008 app delivers its protocol through cognitive-emotional tasks and sensory modulation, aiming to enhance therapeutic outcomes.
growth-positive
Remepy's Mobile App Shown to Rewire Brain, Modulate Immune System and Improve Mood in Adults with Subjective Cognitive Decline
Remepy, a pioneer in hybrid drugs integrating digital and pharmacological interventions, announced that its app-based intervention, RMPY-008, demonstrated significant modulation of inflammatory blood biomarkers in a clinical trial. The study, involving 103 adults, showed that the digital intervention reduced depressive symptoms and improved brain connectivity in individuals with subjective cognitive decline. The findings suggest that RMPY-008 can modulate both brain and immune functions, offering a new therapeutic modality. The app achieved high adherence and engagement, with participants showing sustained benefits. Remepy is commercializing its platform in collaboration with pharmaceutical partners, focusing initially on Parkinsons disease, with plans to expand into fertility, oncology, and immunology.
Product StagePartners
growth-positive
Remepy co-founder Michal Tsur told the Israel Business Conference about the therapy revolution whose time has come.
Remepy, a company co-founded by Dr. Michal Tsur, is pioneering the development of hybrid medications, combining digital applications with traditional drugs. At the 2024 Globes Israel Business Conference, Tsur highlighted the potential of these medications, particularly for Parkinsons disease, following a successful clinical trial. The company aims to revolutionize the pharmaceutical industry by integrating digital treatment protocols with chemical elements, enhancing treatment accessibility and effectiveness. Additionally, Tsur is exploring the establishment of a new airline to offer affordable flights, addressing the current scarcity and high cost of air travel to and from Israel. This initiative reflects the broader trend of high-tech entrepreneurship addressing public sector gaps. Tsur emphasizes the importance of private sector innovation in improving public life, advocating for proactive solutions to societal challenges.
growth-positive
Israeli Startup Combines Software With Medicine To Transform Pharma
Remepy, an Israeli startup, is pioneering the development of hybrid drugs by combining software with traditional medicine. The company has successfully closed a $10 million seed investment round, bringing its total funding to $15 million. The investment was led by NFX and included several other venture firms. Remepy aims to standardize and personalize therapeutic interventions using digital molecules, which have shown promising results in early clinical studies. The company plans to target diseases like Parkinson’s, neurodegenerative diseases, and cancer. Remepy has also announced new board members, including Danny Bar Zohar from Merck and former Israeli Prime Minister Naftali Bennett. The companys approach could potentially halve the time required to bring new drugs to market.
InvestmentManagement ChangesProduct Stage
growth-positive
Remepy raises $10 million Seed round to bring first hybrid drug to market | CTech
Israeli startup Remepy has raised $10 million in a seed investment round, bringing its total funding to $15 million. The round was led by NFX and included participation from Vine Ventures, Psymed Ventures, Supernode Ventures, and Firstime Ventures, among others. Remepy is developing hybrid drugs that combine traditional drugs with its digital molecules, therapeutic interventions that trigger physiological effects through the brain. The company has shown promising results in human studies for Oncology, MCI, and Parkinson’s Disease. Dr. Danny Bar Zohar, Merck’s Global head of R&D and Chief Medical Officer, will be joining the board.
InvestmentManagement Changes
growth-positive
Naftali Bennett and Michal Tsur unite at Remepy: Former PM joins Board for hybrid drug endeavor | CTech
Former Prime Minister of Israel, Naftali Bennett, has joined the board of Remepy, a company co-founded by Dr. Michal Tsur, his former co-founder from Cyota. This is the third high-tech board Bennett has joined since he left politics, previously joining AI cyber company Lasoo and quantum computing startup Quantum Source. Remepy is developing hybrid drugs that include therapeutic applications to enhance the drug effect. The company has demonstrated the physiological effect of its digital interventions in early clinical studies.
Management Changes
growth-positive
Drugs in a Digital World: Shalem Grad Or Shoval '22 Launches Innovative Digital-Health Company - Shalem College
Remepy, an innovative health platform, aims to optimize drugs impact and save more lives by integrating mind and body through cognitive-behavioral exercises and other practices drawn from neuroscience. The company has raised over $2.5M in seed funding and is in negotiations with several Israeli and global pharmaceutical companies and hospitals. Remepys co-founder, Or Shoval, credits his education at Shalem for providing him with the skills and confidence to approach unfamiliar subjects and lead the market validation process. The company is now seeking tier-1 data validation through clinical trials and plans to expand its team of experts.
InvestmentPartners
Remepy Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 59 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
Remepy Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 89/100 |
| Missing | video or image, markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 516671476 |
| Creator | Jenny Sotnik-Talisman |
| Creator email | jenny.sotnik@sncentral.org |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-10-28T00:00:00.000Z |
| Created | 2022-08-31T00:00:00.000Z |
| Claimed | Yes |